A lawsuit investigation is underway regarding the eczema drug Dupixent, which has been linked to cutaneous T-cell lymphoma (CTCL) and mycosis fungoides, a type of skin lymphoma. Some studies reportedly show a higher risk of this rare skin condition in Dupixent users. Allegations also suggest that the link between Dupixent and cancer was withheld from doctors and users, with lawsuits claiming the drug caused CTCL in patients being treated for atopic dermatitis and eczema.